Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10951)
All Articles published online
|
Feb 28, 2009 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol 2009; 15(8): 990-995 [PMID: 19248200 DOI: 10.3748/wjg.15.990] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i8/990.htm |
| Number | Citing Articles |
| 1 |
Vijayalakshmi S. Pratha, Thomas McGraw, William Tobin. A randomized, crossover pharmacodynamic study of immediate‐release omeprazole/sodium bicarbonate and delayed‐release lansoprazole in healthy adult volunteers. Pharmacology Research & Perspectives 2016; 4(3) doi: 10.1002/prp2.238
|
| 2 |
Majid Eslami, Bahman Yousefi, Parviz Kokhaei, Ali Jazayeri Moghadas, Bizhan Sadighi Moghadam, Vahid Arabkari, Zohreh Niazi. Are probiotics useful for therapy of Helicobacter pylori diseases?. Comparative Immunology, Microbiology and Infectious Diseases 2019; 64: 99 doi: 10.1016/j.cimid.2019.02.010
|
| 3 |
Yinglian Xiao, Shutian Zhang, Ning Dai, Guijun Fei, Khean-Lee Goh, Hoon Jai Chun, Bor-Shyang Sheu, Chui Fung Chong, Nobuo Funao, Wen Zhou, Minhu Chen. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 2020; 69(2): 224 doi: 10.1136/gutjnl-2019-318365
|
| 4 |
M. Teng, A. L. Khoo, Y. J. Zhao, L. Lin, B. P. Lim, T. S. Wu, Y. Y. Dan. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori
infection. Journal of Clinical Pharmacy and Therapeutics 2015; 40(4): 368 doi: 10.1111/jcpt.12277
|
| 5 |
Mei-Juan Li, Qing Li, Min Sun, Li-Qin Liu. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis. Medicine 2017; 96(39): e8120 doi: 10.1097/MD.0000000000008120
|
| 6 |
Koji Nakada, Atsushi Oshio, Nobuyuki Matsuhashi, Katsuhiko Iwakiri, Takeshi Kamiya, Noriaki Manabe, Takashi Joh, Kazuhide Higuchi, Ken Haruma. Causal effect of anxiety and depression status on the symptoms of gastroesophageal reflux disease and functional dyspepsia during proton pump inhibitor therapy. Esophagus 2023; 20(2): 309 doi: 10.1007/s10388-022-00960-3
|
| 7 |
Tsung-Hsing Hung, Chih-Wei Tseng, Hsing-Feng Lee, Chih-Chun Tsai, Chen-Chi Tsai. Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. Annals of Hepatology 2018; 17(6): 933 doi: 10.5604/01.3001.0012.7193
|
| 8 |
Sensen Yang, Weishang Deng, Zeyu Xie, Jisheng Chen. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis. Medicine 2022; 101(47): e31807 doi: 10.1097/MD.0000000000031807
|
| 9 |
Abeer Zeitoun, Maya Zeineddine, Hani Dimassi. Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2011; 2(4): 27-35 doi: 10.4292/wjgpt.v2.i4.27
|
| 10 |
Leanne Lai, Goar Alvarez, Aisy Aleu, Caitlan Apping. Cost Avoidance Analysis of Medication Conversions on the Treatment of Gastroesophageal Reflux Disease in a Medication Therapy Management Call Center: A Budgetary Perspective. Journal of Pharmacy Practice 2022; 35(3): 377 doi: 10.1177/0897190020977764
|
| 11 |
F.M. Huerta-Iga, J.L. Tamayo-de la Cuesta, A. Noble-Lugo, J.M. Remes-Troche, M.A. Valdovinos-Díaz, R.I. Carmona-Sánchez. Consenso mexicano de enfermedad por relujo gastroesofágico. Parte I. Revista de Gastroenterología de México 2012; 77(4): 193 doi: 10.1016/j.rgmx.2012.10.002
|
| 12 |
Qianjun Zhuang, Aijun Liao, Qingling He, Chengxia Liu, Changqing Zheng, Xing Li, Youli Liu, Bangmao Wang, Side Liu, Yan Zhang, Rong Lin, Huixin Chen, Min Deng, Yanping Tang, Chiyi He, Weijie Dai, Haitao Tang, Lei Gong, Liangping Li, Baohong Xu, Changqing Yang, Bingxi Zhou, Dongxing Su, Qinghong Guo, Bin Li, Yongjian Zhou, Xiaoyang Wang, Sujuan Fei, Huili Wu, Sichen Wei, Zhihong Peng, Jianning Wang, Yanqing Li, Hong Wang, Tianwei Deng, Shigang Ding, Fangfang Li, Minhu Chen, Yinglian Xiao. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study. Journal of Gastroenterology and Hepatology 2024; 39(4): 658 doi: 10.1111/jgh.16471
|
| 13 |
P. Manjunatha, Y. Arthoba Nayaka, H. T. Purushothama, R. O. Yathisha, M. M. Vinay. Single-walled carbon nanotubes-based electrochemical sensor for the electrochemical investigation of pantoprazole in pharmaceuticals and biological samples. Ionics 2019; 25(5): 2297 doi: 10.1007/s11581-018-2624-1
|
| 14 |
Hideki Mori, Hidekazu Suzuki. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. Journal of Neurogastroenterology and Motility 2019; 25(1): 6 doi: 10.5056/jnm18139
|
| 15 |
Muhammad Rizwan Umer, Wendy E. Mejia Crespo, Sana Dugan, Hamna Javed, Muhammad Suleman, Muhammad Waqas Afzal, Hassan Mumtaz, Muhammad Saqib, Haris Mumtaz Malik, Muhammad Iftikhar. Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial. Annals of Medicine & Surgery 2023; 85(10): 4866 doi: 10.1097/MS9.0000000000001235
|
| 16 |
Lara Aguilera Castro, Carlos Martín de Argila de Prados, Agustín Albillos Martínez. Practical considerations in the management of proton-pump inhibitors. Revista Española de Enfermedades Digestivas 2015; doi: 10.17235/reed.2015.3812/2015
|
| 17 |
Yuping Zhang, Shuyun Shi, Younian Liu, Xiaoqin Chen, Mijun Peng. Differential effects of Cu(II) and Fe(III) on the binding of omeprazole and pantoprazole to bovine serum albumin: Toxic effect of metal ions on drugs. Journal of Pharmaceutical and Biomedical Analysis 2011; 56(5): 1064 doi: 10.1016/j.jpba.2011.08.012
|
| 18 |
Antonio Ruiz de León San Juan, Julio Pérez de la Serna Bueno, María Concepción Sevilla Mantilla, José Miguel Esteban López-Jamar, Andrés Sánchez Pernaute. GASTRO-ESOPHAGEAL REFLUX DISEASE: LIMITS OF MEDICAL TREATMENT AND SURGICAL INDICATIONS. Revista Española de Enfermedades Digestivas 2020; doi: 10.17235/reed.2020.7648/2020
|
| 19 |
Kwang Jae Lee, Byoung Kwan Son, Gwang Ha Kim, Hye‐Kyung Jung, Hwoon‐Yong Jung, Il‐Kwun Chung, In‐Kyung Sung, Jin Il Kim, Jong Hyeok Kim, Joon Seong Lee, Joong Goo Kwon, Jung Ho Park, Kyu Chan Huh, Kyung Sik Park, Moo‐In Park, Nayoung Kim, Oh Young Lee, Sam Ryong Jee, Sang Kil Lee, Sei Jin Youn, Sung Kook Kim, Soo Teik Lee, Su Jin Hong, Suck Chei Choi, Tae Nyeun Kim, Young Hoon Youn, Hyo Ju Park, Min Ja Kang, Chi Hye Park, Bong Tae Kim, Sangjun Youn, Geun Seog Song, Poong‐Lyul Rhee. Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Alimentary Pharmacology & Therapeutics 2019; 49(7): 864 doi: 10.1111/apt.15185
|
| 20 |
Yuping Zhang, Shuyun Shi, Mijun Peng. Investigation of proton pump inhibitors binding with bovine serum albumin and their relationship to molecular structure. Journal of Luminescence 2012; 132(8): 1921 doi: 10.1016/j.jlumin.2012.03.011
|
| 21 |
Mohan Prasad VG, Lynne V. McFarland, Hemant P. Thacker, Rajesh Puri, Parimal S. Lawate, Ziqing Li. Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis. International Journal of Clinical Practice 2024; 2024: 1 doi: 10.1155/2024/9990554
|
| 22 |
Françoise Goirand, Isabelle Le Ray, Marc Bardou. Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism & Toxicology 2014; 10(9): 1301 doi: 10.1517/17425255.2014.939627
|
| 23 |
|
| 24 |
Rajesh Dubey, Jayashree Dubey. Pharmaceutical product differentiation: A strategy for strengthening product pipeline and life cycle management. Journal of Medical Marketing 2009; 9(2): 104 doi: 10.1057/jmm.2009.10
|
| 25 |
Bart Hens, Imke Masuy, Eveline Deloose, Raf Mols, Jan Tack, Patrick Augustijns. Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects. European Journal of Pharmaceutics and Biopharmaceutics 2020; 150: 66 doi: 10.1016/j.ejpb.2020.02.014
|
| 26 |
Risha Kumari, Shweta Agarwal. Role of Proton Pump Inhibitors in the Management of Peptic Ulcer. International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN) 2023; 16(6): 7070 doi: 10.37285/ijpsn.2023.16.6.7
|
| 27 |
R. Abassi, F. Abassi, A. Mosavizadeh, H. Sadeghi, A. Keshtkari. Comparison the Effect of Omeprazole, Esomeprazole and Lansoprazole on Treatment of Gastroesophageal Reflux Disease in Infants. Journal of Clinical Care and Skills 2020; 1(3): 127 doi: 10.52547/jccs.1.3.127
|
| 28 |
Yong-Chul Pyo, Thu Nhan Nguyen, Ye-Seul Lee, Yeong-Eun Choi, Jeong-Sook Park. Design of esomeprazole solid dispersion for improved dissolution and bioavailability using the supercritical anti-solvent technique. Journal of Drug Delivery Science and Technology 2023; 88: 104889 doi: 10.1016/j.jddst.2023.104889
|
| 29 |
M. S. Wu, S. C. Tan, T. Xiong. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro‐oesophageal reflux disease. Alimentary Pharmacology & Therapeutics 2013; 38(2): 190 doi: 10.1111/apt.12349
|
| 30 |
Pawel Petryszyn, Aleksandra Staniak, Jedrzej Grzegrzolka. Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?. Journal of Comparative Effectiveness Research 2016; 5(2): 169 doi: 10.2217/cer.15.63
|
| 31 |
Joaquim Prado P MORAES-FILHO, Gerson DOMINGUES, Decio CHINZON. BRAZILIAN CLINICAL GUIDELINE FOR THE THERAPEUTIC MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE (BRAZILIAN FEDERATION OF GASTROENTEROLOGY, FBG). Arquivos de Gastroenterologia 2024; 61 doi: 10.1590/s0004-2803.24612023-154
|
| 32 |
Maiko Ogawa, Seiji Arihiro, Nobuyuki Matsuhashi, Takashi Joh, Kazuhide Higuchi, Katsuhiko Iwakiri, Takeshi Kamiya, Noriaki Manabe, Kimio Isshi, Tatsuya Nakada, Atsushi Hokari, Masayuki Saruta, Atsushi Oshio, Ken Haruma, Koji Nakada. The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease. Esophagus 2021; 18(2): 398 doi: 10.1007/s10388-020-00792-z
|